New England Journal of Medicine, Lancet, JAMA, BMJ µî ¼¼°è ÃÖ°í ±ÇÀ§ ÀÇÇÐÀú³Î¿¡ ³í¹®À» Åõ°íÇϽôÂ
¼±»ý´ÔµéÀ» À§ÇÑ Àü¹®ÀûÀÎ ÄÁ¼³Æà ¼­ºñ½º¸¦ Á¦°øÇØ µå¸³´Ï´Ù.

---New England Journal of Medicine¿¡ °ÔÀçµÈ Çѱ¹ÀÎ ÀúÀÚµéÀÇ Original article »ç·Ê ºÐ¼®


Title Study design
N (Sample size)
ClinicalTrials.gov Identifier:
Sponsors
Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents
http://www.nejm.org/doi/full/10.1056/NEJMoa1001266
Prospective RCT
N=2,701
NCT00484926 and NCT00590174
N/A
Low-Dose Abdominal CT for Evaluating Suspected Appendicitis
http://www.nejm.org/doi/full/10.1056/NEJMoa1110734
Prospective RCT
N = 891
NCT00913380
GE Healthcare
Randomized Trial of Stents versus Bypass Surgery for Left Main Coronary Artery Disease
http://www.nejm.org/doi/full/10.1056/NEJMoa1100452
Prospective RCT
N = 600
NCT00422968
Johnson&Johnson Cordis
A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis
http://www.nejm.org/doi/full/10.1056/NEJMoa021007
Prospective RCT
N = 177
Boston Scientific
Early Surgery versus Conventional Treatment for Infective Endocarditis
http://www.nejm.org/doi/full/10.1056/NEJMoa1112843
Prospective RCT
N = 76
NCT00750373
N/A
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
http://www.nejm.org/doi/full/10.1056/NEJMoa1201964
Prospective RCT
N = 41
NCT00727844
N/A
Body-Mass Index and Mortality in Korean Men and Women
http://www.nejm.org/doi/full/10.1056/NEJMoa054017
Prospective cohort study
N = 1,213,829
N/A
Stents versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease
http://www.nejm.org/doi/full/10.1056/NEJMoa0801441
Retrospective cohort study
N = 2,240
N/A


NEJM¿¡ Original article·Î °ÔÀçµÈ Çѱ¹ÀÎ ÀúÀÚµéÀÇ ³í¹®Àº ÀüºÎ 8 ÆíÀÌ °Ë»öÀÌ µÇ°í ´ë»ó ȯÀÚ¼ö¿Í Study designÀ¸·Î
ºÐ·ùÇÑ °á°ú ´ë±Ô¸ð ¹«ÀÛÀ§ ¹èÁ¤ ÀÓ»ó½ÃÇèÀÌ ¾ÐµµÀûÀ¸·Î ´Ù¼ö¸¦ Â÷ÁöÇÏ°í ÀÖ½À´Ï´Ù.

ÀϹÝÀûÀ¸·Î Impact factor°¡ ³ôÀº ÀÇÇÐÀú³Î¿¡ ³í¹®À» ¼º°øÀûÀ¸·Î °ÔÀçÇϽ÷Á¸é ´ÙÀ½°ú °°Àº ¿ä¼ÒµéÀ»
°í·ÁÇÏ¼Å¾ß ÇÕ´Ï´Ù.

Originality (µ¶Ã¢¼º):
  ±âÁ¸ ¹®Çå¿¡ º¸°íµÇÁö ¾ÊÀº Âü½ÅÇÑ ÁÖÁ¦

Sample size (´ë»ó ȯÀÚ¼ö):
  ÃÖÁ¾ µî·Ï ȯÀÚ¼ö°¡ ´ë±Ô¸ðÀÎ ¿¬±¸Àϼö·Ï °ÔÀç¿¡ À¯¸®ÇÕ´Ï´Ù.

Study design (¿¬±¸ ¼³°è):
  ClinicalTrials.gov¿¡ µî·ÏµÈ ¹«ÀÛÀ§ ¹èÁ¤¿¬±¸ÀÎ °æ¿ì °ÔÀç¿¡ À¯¸®ÇÕ´Ï´Ù.

Non-Korean setting (Çѱ¹ÀÇ ÀÇ·á ȯ°æ¿¡ ÀûÇÕÇÑ ³»¿ë º¸´Ù´Â ¿µ¾î±Ç ±¹°¡ÀÇ µ¶Àڵ鿡°Ô Èï¹Ì·Î¿î ÁÖÁ¦):
  Çѱ¹ ƯÁ¤ Áö¿ª¿¡¼­ ½Ç½ÃÇÑ ¿ªÇÐ ¿¬±¸, ±¹³» Á¦¾à»ç Ãâ½Ã ÀǾàÇ° ÀÓ»ó½ÃÇè µîÀº °ÔÀç °¡´É¼ºÀÌ »ó´ëÀûÀ¸·Î ³·½À´Ï´Ù.

Clinical study (Àӻ󿬱¸):
  »ç¶÷(human subject)À» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Àӻ󿬱¸¸¦ ´ë»óÀ¸·Î peer-review¸¦ ÇÏ¸ç µ¿¹°½ÇÇè
  ¶Ç´Â ¼¼Æ÷ÁÖ ¿¬±¸ µîÀº peer-reviewÀÇ °í·Á ´ë»ó¿¡¼­ Á¦¿ÜµË´Ï´Ù.




MD PhD´Â NEJM, Lancet, JAMA, BMJ µî ÃÖ°í ±ÇÀ§ ±¹Á¦ ÀÇÇÐ ÇмúÁö¿¡
¼º°øÀûÀ¸·Î °ÔÀçÇϱâ À§ÇÑ ¿µ¹®È­ ¼Ö·ç¼Ç
À» Á¦°øÇØ µå¸³´Ï´Ù.

(1) ¿ø¹® »óÀÇ ¿À·ù Á¦°Å
(2) ³íÁö Àü°³ ¹æ½ÄÀÇ Á¡°Ë¿¡ ÀÇÇÑ logical backboneÀÇ Çü¼º
(3) º»¹® ¿ä¾à¿¡ ÀÇÇÑ ÃÊ·Ï »ý¼º
(4) ÃÊ·ÏÀÇ ÇÑÁÙ ¿ä¾à¿¡ ÀÇÇÑ Á¦¸ñ »ý¼º
(5) ¿¬±¸ ³í¹®ÀÇ °¡Ä¡ Àü´ÞÀ» À§ÇÑ Ä¿¹ö·¹ÅÍ »ý¼º